De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!
Hims & Hers Health Toekomstige groei
Future criteriumcontroles 6/6
Hims & Hers Health zal naar verwachting groeien in winst en omzet met respectievelijk 41.3% en 22.4% per jaar. De winst per aandeel zal naar verwachting groeien met 38.3% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting 25.1% zijn.
Belangrijke informatie
41.3%
Groei van de winst
38.3%
Groei van de winst per aandeel
Healthcare winstgroei | 19.3% |
Inkomstengroei | 22.4% |
Toekomstig rendement op eigen vermogen | 25.1% |
Dekking van analisten | Good |
Laatst bijgewerkt | 01 Oct 2024 |
Recente toekomstige groei-updates
Recent updates
Hims & Hers: Shortage Saga Brings Stupendous Risk-Reward
Oct 03Hims & Hers Health, Inc.'s (NYSE:HIMS) P/S Is Still On The Mark Following 25% Share Price Bounce
Oct 01Hims & Hers Is Unbelievably Cheap And Profitable: Buy Now
Sep 24Hims & Hers Health Post Q2 Earnings - Compounded GLP-1 Ploy Faces New Threats (Rating Downgrade)
Aug 27Hims & Hers: Digesting Q2 2024 Earnings, Shares Still Undervalued, Rating Downgrade
Aug 20Hims & Hers Health, Inc.'s (NYSE:HIMS) Share Price Is Still Matching Investor Opinion Despite 27% Slump
Aug 11Hims & Hers Health: Buy The Dip, With Or Without The GLP-1 Shortage
Aug 07Hims & Hers: The Thesis Goes Far Beyond GLP-1
Jul 18Hims & Hers: Buy The Dip To Catch The Next Rip
Jun 24Why Investors Shouldn't Be Surprised By Hims & Hers Health, Inc.'s (NYSE:HIMS) 70% Share Price Surge
Jun 19Hims & Hers: The Undervalued Gem Poised For Growth
Jun 18Beyond The Marketing Machine: Why Hims & Hers Stock Might Be Vulnerable
Jun 10Hims & Hers Health, Inc.'s (NYSE:HIMS) CEO Compensation Is Looking A Bit Stretched At The Moment
May 31Hims & Hers: Soaring On Access To Compounded GLP-1 Drugs, Further Volatility Ahead
May 21Hims & Hers Health: An Unforced Error
May 06Hims & Hers Health, Inc. (NYSE:HIMS) Stocks Pounded By 27% But Not Lagging Industry On Growth Or Pricing
May 04Hims & Hers Health: Becoming A Market Leader Within The Growing Digital Health Industry
Apr 24Hims & Hers Health: Strong Prospects But Weak Business Model Consolidation
Apr 05Hims & Hers: 5 Reasons Why This Is A Phenomenal Long-Term Growth Stock
Mar 21Pills Pay The Bills: Mini Deep Dive On Hims & Hers Health
Mar 12Investors Appear Satisfied With Hims & Hers Health, Inc.'s (NYSE:HIMS) Prospects As Shares Rocket 49%
Feb 28Hims & Hers: Turning The Profitability Corner And Returning 28%
Feb 25Hims & Hers Health: No Clear Moat Besides First Mover Advantage
Jan 23Hims & Hers Health: Unleashing Macro Momentum - Investing In Growth At A Higher Multiple
Jan 10Investors Still Waiting For A Pull Back In Hims & Hers Health, Inc. (NYSE:HIMS)
Jan 07Hims & Hers Health Q3: The Cheapest Growth Stock Around
Dec 14Hims & Hers Health: What Would The Author Of 100 Baggers Say?
Nov 30Hims & Hers: The Most Undervalued Small Cap Stock I See
Nov 08Hims & Hers: A Promising Company With Resolvable Challenges
Nov 02Hims & Hers: Specialization Is The Secret To Great Growth
Oct 25Hims & Hers Health: Can't Get Much Better
Sep 25The Market Is Wrong On Hims & Hers Health
Sep 18Hims & Hers: The Current Weakness Creates A Buying Opportunity
Aug 15Hims & Hers Health: Giving Investors Another Bite At The Apple
Aug 01Hims & Hers Health, Inc.'s (NYSE:HIMS) Price In Tune With Revenues
Jul 21Hims & Hers Health: Expect Strong EBITDA Growth As Revenue Growth Remains Strong
Jul 13Hims & Hers Health: Double-Edged Sword
Jul 02Winst- en omzetgroeiprognoses
Datum | Inkomsten | Inkomsten | Vrije kasstroom | Geldmiddelen uit operationele activiteiten | Gem. Aantal analisten |
---|---|---|---|---|---|
12/31/2026 | 2,289 | 144 | 274 | 336 | 12 |
12/31/2025 | 1,896 | 106 | 195 | 251 | 14 |
12/31/2024 | 1,390 | 49 | 110 | 195 | 14 |
6/30/2024 | 1,067 | 18 | 90 | 127 | N/A |
3/31/2024 | 959 | -2 | 52 | 90 | N/A |
12/31/2023 | 872 | -24 | 47 | 73 | N/A |
9/30/2023 | 793 | -36 | 27 | 45 | N/A |
6/30/2023 | 711 | -47 | 12 | 26 | N/A |
3/31/2023 | 616 | -59 | -6 | 2 | N/A |
12/31/2022 | 527 | -66 | -34 | -27 | N/A |
9/30/2022 | 444 | -86 | -29 | -23 | N/A |
6/30/2022 | 374 | -83 | -51 | -45 | N/A |
3/31/2022 | 321 | -73 | -43 | -38 | N/A |
12/31/2021 | 272 | -108 | -39 | -34 | N/A |
9/30/2021 | 229 | -82 | -36 | -32 | N/A |
6/30/2021 | 196 | -72 | -17 | -12 | N/A |
3/31/2021 | 171 | -63 | -18 | -13 | N/A |
12/31/2020 | 149 | -18 | -7 | -2 | N/A |
9/30/2020 | 132 | -25 | -16 | -13 | N/A |
6/30/2020 | 112 | -38 | -43 | -41 | N/A |
3/31/2020 | 95 | -58 | -62 | -60 | N/A |
12/31/2019 | 83 | -72 | -77 | -75 | N/A |
12/31/2018 | 27 | -75 | -57 | -57 | N/A |
Toekomstige groeivoorspellingen analisten
Verdiensten versus spaarpercentage: De verwachte winstgroei HIMS ( 41.3% per jaar) ligt boven de spaarquote ( 2.5% ).
Winst versus markt: De winst van HIMS ( 41.3% per jaar) zal naar verwachting sneller groeien dan de US markt ( 15.2% per jaar).
Hoge groeiwinsten: De winst van HIMS zal naar verwachting de komende 3 jaar aanzienlijk groeien.
Omzet versus markt: De omzet van HIMS ( 22.4% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.7% per jaar).
Hoge groei-inkomsten: De omzet van HIMS ( 22.4% per jaar) zal naar verwachting sneller groeien dan 20% per jaar.
Groeiprognoses winst per aandeel
Toekomstig rendement op eigen vermogen
Toekomstige ROE: Het rendement op eigen vermogen HIMS zal naar verwachting over 3 jaar hoog zijn ( 25.1 %)